Evidence map›Paper›PMID 41953502›Full record

ArticleCase reports in oncological medicine2026

Drug Interaction Between Erlotinib and Itraconazole in a Patient With Non-Small Cell Lung Cancer.

Hayato Yokota, Satoshi Goshima, Yuji Okuda, Sho Sakamoto, Masahide Takeda, Kazuhiro Sato, Yumiko Akamine, Katsutoshi Nakayama, Masatomo Miura

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Case reports in oncological medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Hayato YokotaDepartment of Pharmacy, Akita University Hospital, Akita, Japan, akita-u.ac.jp.ORCID https://orcid.org/0000-0003-1389-435X
Satoshi GoshimaDepartment of Internal Medicine, Division of Respiratory Medicine, Akita University School of Medicine, Akita, Japan, akita-u.ac.jp.
Yuji OkudaDepartment of Internal Medicine, Division of Respiratory Medicine, Akita University School of Medicine, Akita, Japan, akita-u.ac.jp.
Sho SakamotoDepartment of Internal Medicine, Division of Respiratory Medicine, Akita University School of Medicine, Akita, Japan, akita-u.ac.jp.
Masahide TakedaDepartment of Internal Medicine, Division of Respiratory Medicine, Akita University School of Medicine, Akita, Japan, akita-u.ac.jp.
Kazuhiro SatoDepartment of Internal Medicine, Division of Respiratory Medicine, Akita University School of Medicine, Akita, Japan, akita-u.ac.jp.
Yumiko AkamineDepartment of Pharmacy, Akita University Hospital, Akita, Japan, akita-u.ac.jp.ORCID https://orcid.org/0000-0002-1346-757X
Katsutoshi NakayamaDepartment of Internal Medicine, Division of Respiratory Medicine, Akita University School of Medicine, Akita, Japan, akita-u.ac.jp.
Masatomo MiuraDepartment of Pharmacy, Akita University Hospital, Akita, Japan, akita-u.ac.jp.ORCID https://orcid.org/0000-0001-7120-2425

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Erlotinib (ERL) is metabolized primarily by cytochrome P450 (CYP) 3A4. We report a case of non-small cell lung cancer in which plasma ERL concentrations increased following coadministration of itraconazole (ITCZ). Case Presentation: In this patient, a 67-year-old man receiving ERL 150 mg/day, the trough plasma concentration ( Conclusion: Even at the relatively lower

Indexed as

drug–drug interactionerlotinibitraconazolenon–small cell lung cancertrough plasma concentration

Identifiers

PMID41953502
PMCPMC13054510

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.